Biomarker ID | 1045 |
PMID | 23342084 |
Year | 2013 |
Biomarker | Early Growth Response 1 (Egr1) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Relapse (0.784 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Differentiation pathway in PC12 cells, Regular glucocorticoid receptor pathway, PI3K/PLC/TRK pathway, Signaling events mediated by hepatocyte growth factor receptor (c-Met), RANKL regulation of apoptosis and immune response |
Experiment | Relpase Vs No Relapse |
Type of Biomarker | Prognostic |
Cohort | Relapsed samples (n=38) and non relapsed samples (n=63) were chosen for the study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p = 0.017 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | The outcome parameter ‘‘relapse’’ refers to biochemical relapse, the rise in PSA levels over 0.2 ng/ml following a prior post-op PSA that was below threshold for the test. Non-relapse means that no biochemical relapse was observed in the patient during the clinical follow-up time frame. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |